Riskpilot← Back to searchSign inGet full accessPHARMARELATIONS AS
ASActiveOrg 920388353Nydalen 28, 0484 OsloActivities of employment placement agencies · NACE 7810Est. 201810 employees
Revenue 2024
NOK 31,1M
+50% vs 2023
EBITDA margin
7.1%
+765% vs 2023
Equity ratio
44.0%
Financial strength
Net profit 2024
NOK 1,8M
+629% vs 2023
| Revenue | NOK 31,1M | +50% |
| EBITDA | NOK 2,2M | +765% |
| Net profit | NOK 1,8M | +629% |
| Total assets | NOK 10,4M | +64% |
| Equity | NOK 4,6M | +63% |
| Employees | 10 | — |
Legal name
PHARMARELATIONS AS
Org number
920388353
Legal form
Aksjeselskap
NACE code
7810 · Activities of employment placement agencies
Founded
19. februar 2018
Share capital
NOK 30 000
Employees
10 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
To styremedlemmer i fellesskap.
Company purpose
Konsulentselskap for livskunnskap som rekruttering, utøvende søkt, konsulenttjenester, midlertidig bemanning og outsourcing.
Address
Nydalen 28, 0484 Oslo
Phone
+4790952128
Email
sverre.slaastad@pharmarelations.no
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Revenue | 4 783 | 13 734 | 11 605 | 11 106 | 20 206 | 20 651 | 31 061 |
| Staff expenses | −3 966 | −9 506 | −9 315 | −7 853 | −13 103 | −15 437 | −22 402 |
| EBITDA | 0 | 1 040 | −270 | 877 | 2 404 | −334 | 2 219 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 | −0 | −0 |
| EBIT | 0 | 1 040 | −270 | 877 | 2 404 | −334 | 2 219 |
| Net financials | 0 | −25 | 6 | −9 | −7 | 0 | −26 |
| Profit before tax | 1 | 1 016 | −264 | 867 | 2 397 | −334 | 2 193 |
| Tax | −0 | 222 | −57 | 192 | 527 | −0 | 428 |
| Net profit | 1 | 794 | −207 | 675 | 1 869 | −334 | 1 765 |
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Total assets | 2 755 | 4 176 | 3 621 | 4 128 | 8 522 | 6 363 | 10 435 |
| Equity | 24 | 817 | 611 | 1 286 | 3 155 | 2 822 | 4 587 |
| Long-term debt | 1 361 | 661 | 1 383 | 1 083 | 1 115 | 0 | 0 |
| Short-term debt | 1 370 | 2 698 | 1 627 | 1 759 | 4 252 | 3 541 | 5 848 |
| Total debt | 2 731 | 3 359 | 3 011 | 2 842 | 5 367 | 3 541 | 5 848 |
EBITDA margin
7.1%
This company
15.8%
Market median
-55% vs market
20182024
Equity ratio
44.0%
This company
38.2%
Market median
+15% vs market
20182024
Return on equity
38.5%
This company
18.4%
Market median
+109% vs market
20182024
Net profit margin
5.7%
This company
8.1%
Market median
-30% vs market
20182024
Asset turnover
2.98×
This company
1.12×
Market median
+166% vs market
20182024
Debt / equity
1.28×
This company
0.62×
Market median
-106% vs market
20182024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Brønnøysundsregistrene · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Brønnøysundsregistrene · Period 2018-01-01 – 2018-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
LØ Chief Executive Officer | Chief Executive Officer | 2024 | — | — |
SA Chief Executive Officer | Chief Executive Officer | 2020 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2025 | — | — | |
| Board of Directors | 2018 | — | — | |
| Board of Directors | 2018 | — | — | |
| Chairman | 2018 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Pharmarealtions Ab | Company | 100.0% | 100.0% | 2023 |
Pharmarelations Ab | Company | 100.0% | 100.0% | 2024 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of PHARMARELATIONS AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Liv Østbye | Chief Executive Officer | 0 companies |
| Sverre Arne Slaastad | Chief Executive Officer | 0 companies |
| Åsa Maria Uppströmer | Board of Directors | 0 companies |
| Yvonne Linnea Marie Hedlund | Board of Directors | 0 companies |
| Fredrik Gunnar Åke Anjou | Board of Directors | 0 companies |
| Lena Birgitta Andersson Hofsberger | Chairman | 0 companies |